Background: Innate and acquisition of resistance to cetuximab, an epithelial growth factor receptor (EGFR) blocker, is major problem in metastatic head and neck squamous cell carcinoma (HNSCC). Although cetuximab…
squamous cell carcinoma (HNSCC), making decisions regarding anticancer agent use and other treatments difficult. Cetuximab, an anticancer drug used as molecular targeted therapy, is administered irrespective of patient…
Objectives: Cetuximab is an anticancerous drug which causes oral mucositis as a major side effect. Oral mucositis can be reduced by the effect of grape seed extract which modulates ... inflammatory pathways. Our aim is…
this study, we examined the effect of cetuximab (epidermal growth factor receptor monoclonal antibody) combined with afatinib (epidermal growth factor receptorand human epidermal growth factor receptor 2 tyrosine kinase…
objective of the present study was to develop PLGA nanoparticles surface modified with cetuximab to deliver in a targeted fashion sorafenib into undifferentiated/anaplastic thyroid carcinoma cell line ... vitro drug…
literature. Although these reactions occur more frequently with earlier generation antibodies such as cetuximab, which contains 34% murine protein, the risk of immunogenicity is still present with fully human…
Background: There are few evidence which kind of tumor is more benefit from cetuximab, more investigations of supplementary predictive factors are highly relevant. The purpose is to evaluate the prognostic ... utility…
study the efficacy, response of weekly cetuximab used concurrently with radiotherapy versus weekly cisplatin with concurrent radiotherapy in loco regionally advanced Head and Neck Squamous Cell Carcinoma (HNSCC)…
pembrolizumab) or dysregulated tumorigenic pathways (e.g. the chimeric Immunoglobulin (Ig) G1 monoclonal antibody cetuximab that binds the extracellular domain of EGFR has shown to increase curation rates in…
still unclear. The present study aimed to examine the costeffectiveness of regorafenib compared to cetuximab plus irinotecan in the Chinese setting. Methods: A Markov model was constructed to conduct ... model projected…
main objective behind conducting this study was to conduct an economic evaluation of cetuximab with radiotherapy versus radiotherapy alone in treatment of LASCCHN from the payer perspective (the Ministry ... Time…
Cetuximab is a mouse-human chimeric monoclonal antibody, approved for marketing to treat patients with advanced colorectal cancer and head and neck squamous cell carcinoma in several countries around ... signals or…
epidermal growth factor receptor. Its utility as a salvage therapy is unknown in cetuximab-resistant colorectal cancer. We assessed the prognostic and predictive role of circulating tumor cells (CTCs ... KRAS wild-type…
oral mucositis in treatment for head and neck cancer with radiotherapy and concurrent cetuximab and to determine whether it has different characteristics from mucositis caused by other drugs. Materials ... squamous cell…
Background: We prospectively compared FLT-PET and FDG-PET in evaluating response to cetuximab and chemoradiotherapy for HNSCC. Methods: Six patients with HNSCC received cetuximab followed by chemoradiotherapy. Patients…
Cetuximab, a monoclonal antibody targeting epidermal growth factor receptor, has proven to be efficient in the treatment of metastatic colorectal cancer. We made a prospective study of the efficacy ... toxicities of…
increase attractive electrostatic dimerization, hence stabilizing the activating dimer configuration. EGFR antibodies such as cetuximab that interfere with dimerization may lead to responses. We identified three…
H1299) and epirubicin resistant (R-H1299) lung cancer cells. These cells were treated with cetuximab (C225, Erbitux, a chimeric anti-epidermal growth factor receptor (EGFR) monoclonal antibody) alone and combined…
Objective: To discuss clinical therapeutic effects of hepatic arterial chemoembolization combined with cetuximab on patients with colorectal liver metastases. Methods: 50 patients with colorectal liver metastases…
pivotal phase II and III studies, the targeting monoclonal antibody cetuximab has been shown to improve the efficacy of standard chemotherapy regimens used in first-line treatment of metastatic colorectal ... cancer…
main objective behind conducting this study was to conduct an economic evaluation of cetuximab with radiotherapy versus radiotherapy alone in treatment of LASCCHN from the payer perspective (the Ministry ... Time…
Purpose: This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with metastatic colorectal cancer ... enrolled into this study from…
oral squamous cell carcinoma is crucial for preventing the development of the disorder. The cetuximab has been testified in oral squamous cell carcinoma patients, while the accurate targeting is still ... squamous cell…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.